J P Morgan Chase & Co Reiterates Buy Rating for Incyte Corporation (INCY)

Incyte Corporation (NASDAQ:INCY)‘s stock had its “buy” rating reaffirmed by equities research analysts at J P Morgan Chase & Co in a note issued to investors on Tuesday.

A number of other research analysts have also weighed in on INCY. Cowen and Company restated an “outperform” rating and set a $130.00 price objective on shares of Incyte Corporation in a research report on Monday, July 3rd. Barclays PLC raised their price objective on Incyte Corporation from $135.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday, July 4th. Jefferies Group LLC restated a “buy” rating and set a $165.00 price objective on shares of Incyte Corporation in a research report on Tuesday, July 4th. BidaskClub lowered Incyte Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, July 6th. Finally, Credit Suisse Group set a $152.00 price objective on Incyte Corporation and gave the company a “buy” rating in a research report on Sunday, July 16th. Seven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $144.98.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. During the same quarter in the prior year, the business posted $0.19 EPS. Incyte Corporation’s revenue for the quarter was up 41.6% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: “J P Morgan Chase & Co Reiterates Buy Rating for Incyte Corporation (INCY)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2017/11/02/j-p-morgan-chase-co-reiterates-buy-rating-for-incyte-corporation-incy.html.

In related news, insider Paul Trower sold 3,000 shares of Incyte Corporation stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $125.25, for a total transaction of $375,750.00. Following the transaction, the insider now directly owns 11,853 shares of the company’s stock, valued at $1,484,588.25. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bros. Advisors Lp Baker acquired 100,000 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were acquired at an average cost of $132.00 per share, for a total transaction of $13,200,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 101,147 shares of company stock worth $12,615,101. 17.70% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. Oppenheimer Asset Management Inc. increased its holdings in Incyte Corporation by 9.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 27,147 shares of the biopharmaceutical company’s stock valued at $3,418,000 after buying an additional 2,455 shares during the period. Pinebridge Investments L.P. increased its holdings in Incyte Corporation by 122.0% during the second quarter. Pinebridge Investments L.P. now owns 74,590 shares of the biopharmaceutical company’s stock valued at $9,392,000 after buying an additional 40,992 shares during the period. Calamos Advisors LLC increased its holdings in Incyte Corporation by 37.7% during the second quarter. Calamos Advisors LLC now owns 113,132 shares of the biopharmaceutical company’s stock valued at $14,244,000 after buying an additional 30,990 shares during the period. Tredje AP fonden increased its holdings in Incyte Corporation by 63.4% during the second quarter. Tredje AP fonden now owns 22,446 shares of the biopharmaceutical company’s stock valued at $2,826,000 after buying an additional 8,706 shares during the period. Finally, Inverness Counsel LLC NY purchased a new position in Incyte Corporation during the third quarter valued at approximately $330,000. 88.85% of the stock is currently owned by institutional investors.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

What are top analysts saying about Incyte Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Incyte Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit